Literature DB >> 27869291

Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum.

S A Waldman1, A Terzic2.   

Abstract

Success in pharmaceutical development led to a record 51 drugs approved in the past year, surpassing every previous year since 1950. Technology innovation enabled identification and exploitation of increasingly precise disease targets ensuring next generation diagnostic and therapeutic products for patient management. The expanding biopharmaceutical portfolio stands, however, in contradistinction to the unsustainable costs that reflect remarkable challenges of clinical development programs. This annual Therapeutic Innovations issue juxtaposes advances in translating molecular breakthroughs into transformative therapies with essential considerations for lowering attrition and improving the cost-effectiveness of the drug-development paradigm. Realizing the discovery-translation-application continuum mandates a congruent approval, adoption, and access triad.
© 2016 ASCPT.

Entities:  

Mesh:

Year:  2016        PMID: 27869291      PMCID: PMC5764073          DOI: 10.1002/cpt.551

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Regenerative medicine legislation in Japan for fast provision of cell therapy products.

Authors:  Y Fujita; A Kawamoto
Journal:  Clin Pharmacol Ther       Date:  2015-11-20       Impact factor: 6.875

2.  Precision Medicine.

Authors:  M Pacanowski; S M Huang
Journal:  Clin Pharmacol Ther       Date:  2016-02       Impact factor: 6.875

3.  Novel approaches to address challenges in global drug development.

Authors:  B P Smith; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2015-01-22       Impact factor: 6.875

Review 4.  Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Authors:  H M Jones; Y Chen; C Gibson; T Heimbach; N Parrott; S A Peters; J Snoeys; V V Upreti; M Zheng; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2015-01-09       Impact factor: 6.875

5.  Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.

Authors:  A Parekh; S Buckman-Garner; S McCune; R ONeill; M Geanacopoulos; S Amur; C Clingman; R Barratt; M Rocca; I Hills; J Woodcock
Journal:  Clin Pharmacol Ther       Date:  2015-01-28       Impact factor: 6.875

6.  Intelligent pharmaceuticals: beyond the tipping point.

Authors:  P Honig; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2014-05       Impact factor: 6.875

7.  Improving therapeutic effectiveness and safety through big healthcare data.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2016-01-17       Impact factor: 6.875

Review 8.  Longitudinal cystic fibrosis care.

Authors:  S S Antunovic; M Lukac; D Vujovic
Journal:  Clin Pharmacol Ther       Date:  2012-11-14       Impact factor: 6.875

Review 9.  Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.

Authors:  K Venkatakrishnan; L E Friberg; D Ouellet; J T Mettetal; A Stein; I F Trocóniz; R Bruno; N Mehrotra; J Gobburu; D R Mould
Journal:  Clin Pharmacol Ther       Date:  2014-12-09       Impact factor: 6.875

Review 10.  Regenerative Medicine Build-Out.

Authors:  Andre Terzic; Michael A Pfenning; Gregory J Gores; C Michel Harper
Journal:  Stem Cells Transl Med       Date:  2015-11-04       Impact factor: 6.940

View more
  3 in total

1.  Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-09       Impact factor: 6.875

2.  Process Improvement for Maximized Therapeutic Innovation Outcome.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2018-01       Impact factor: 6.875

3.  Health Care Evolves From Reactive to Proactive.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.